WILMINGTON, Del., May 7, 2026
Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had inadequate response, intolerance, or contraindications to standard topical therapies including corticosteroids and calcineurin inhibitors. The data, presented at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium in Athens, Greece, demonstrated sustained disease control, strong efficacy outcomes, and a favorable long-term safety profile for the nonsteroidal topical treatment.
The latest findings strengthen Incyte’s position in the growing inflammatory dermatology market, where demand continues increasing for targeted therapies capable of delivering long-term symptom relief while reducing reliance on steroids and systemic treatments. Researchers and clinicians say moderate atopic dermatitis remains a major therapeutic challenge for many adults who fail to achieve adequate disease control using conventional topical medications.
Opzelura Maintains Strong Efficacy Through 24 Weeks
According to the Phase 3 TRuE-AD4 study results, patients who responded to Opzelura treatment during the initial 8-week period continued demonstrating durable disease control through Week 24 using as-needed therapy. Investigators reported that 84.3% of patients achieved EASI75, representing at least a 75% improvement in the Eczema Area and Severity Index score from baseline, while 70.6% achieved Investigator’s Global Assessment Treatment Success (IGA-TS) after continuing treatment through Week 24.
The study also showed that the mean affected body surface area remained consistently low at 2.5% during both Weeks 8 and 24, while itch relief remained high among treated patients. Approximately 64.7% of participants maintained clinically meaningful itch reduction using the Itch Numeric Rating Scale at Week 24, highlighting the treatment’s ability to sustain symptom improvement over time.
Advertisement
Researchers noted that the trial previously met both of its co-primary endpoints at Week 8, with statistically significant improvements observed in both EASI75 and IGA Treatment Success compared with vehicle cream. These long-term findings provide additional evidence supporting Opzelura as a differentiated nonsteroidal treatment option for adults with moderate atopic dermatitis who have limited alternatives after failing conventional therapies.
Long-Term Safety Profile Supports Continued Development
Incyte stated that Opzelura remained well tolerated throughout the 24-week study period, with very few application site reactions reported. Only 1.7% of patients experienced treatment-site reactions, and no new safety signals emerged during long-term treatment. The most commonly reported treatment-emergent adverse events included upper respiratory tract infections and nasopharyngitis.
The company emphasized that the safety findings are particularly important as healthcare providers increasingly seek chronic dermatology therapies capable of balancing efficacy with long-term tolerability. Opzelura is a topical formulation of ruxolitinib, a selective JAK1/JAK2 inhibitor, and has already received approval in the United States for treatment of mild-to-moderate atopic dermatitis and nonsegmental vitiligo.
Incyte also confirmed that the new data support its Type-II variation application submitted in the European Union seeking expanded approval of ruxolitinib cream for adults with moderate atopic dermatitis. Regulatory feedback from European authorities is expected during the first half of 2026.
Atopic Dermatitis Market Continues Expanding
Atopic dermatitis remains one of the world’s most common chronic inflammatory skin disorders, affecting up to 12% of adults globally. The condition is characterized by severe itching, inflammation, skin lesions, and recurring flare-ups that can significantly impact quality of life.
Industry analysts believe demand for targeted nonsteroidal dermatology therapies will continue expanding as physicians and patients increasingly prioritize treatments that reduce long-term steroid exposure and improve disease management. Companies developing advanced topical immunology therapies are expected to remain highly competitive as regulatory approvals and new clinical data continue shaping the future inflammatory skin disease market.
Source: Incyte press release
